Literature DB >> 2068099

Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.

C Y Kang1, P Nara, S Chamat, V Caralli, T Ryskamp, N Haigwood, R Newman, H Köhler.   

Abstract

Total anti-gp120 antibodies (total anti-gp120 Abs) were purified from a pool of four human immunodeficiency virus-positive (HIV+) sera by affinity chromatography on a gp120SF2-Sepharose column and exhibited both type- and group-specific neutralizing activities. To dissect the epitope specificity of the group-specific neutralizing antibodies, CD4 attachment site-specific antibodies (CD4-site Abs) were isolated from total anti-gp120 Abs by using a CD4-blocked gp120SF2-Sepharose column. The CD4-site Abs exhibited group-specific neutralizing activities. Another approach to dissecting type- and group-specific neutralizing activities of total anti-gp120 Abs was to separate the third variable region (V3)-specific antibodies (V3-region Abs) from non-V3-region-specific antibodies (non-V3 Abs). The results indicated that V3-region Abs exhibited type-specific neutralizing activities, whereas non-V3 Abs exhibited group-specific neutralizing activities. By comparing the neutralizing activities of V3-region Abs to those of non-V3 Abs, we concluded that V3-region Abs are more effective than non-V3 Abs in neutralizing a specific HIV isolate. Collectively, this study indicates that group-specific neutralizing anti-gp120 antibodies are specific for the CD4 attachment site.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2068099      PMCID: PMC52044          DOI: 10.1073/pnas.88.14.6171

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

1.  Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1.

Authors:  M Kowalski; J Potz; L Basiripour; T Dorfman; W C Goh; E Terwilliger; A Dayton; C Rosen; W Haseltine; J Sodroski
Journal:  Science       Date:  1987-09-11       Impact factor: 47.728

2.  Quantitative infectivity assay for HIV-1 and-2.

Authors:  P L Nara; P J Fischinger
Journal:  Nature       Date:  1988-03-31       Impact factor: 49.962

3.  The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion?

Authors:  G J Clements; M J Price-Jones; P E Stephens; C Sutton; T F Schulz; P R Clapham; J A McKeating; M O McClure; S Thomson; M Marsh
Journal:  AIDS Res Hum Retroviruses       Date:  1991-01       Impact factor: 2.205

4.  HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex.

Authors:  M Robert-Guroff; M Brown; R C Gallo
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

5.  Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients.

Authors:  R A Weiss; P R Clapham; R Cheingsong-Popov; A G Dalgleish; C A Carne; I V Weller; R S Tedder
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

6.  Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.

Authors:  J Goudsmit; C Debouck; R H Meloen; L Smit; M Bakker; D M Asher; A V Wolff; C J Gibbs; D C Gajdusek
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

7.  Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope.

Authors:  S Matsushita; M Robert-Guroff; J Rusche; A Koito; T Hattori; H Hoshino; K Javaherian; K Takatsuki; S Putney
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

8.  Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein.

Authors:  M A Skinner; R Ting; A J Langlois; K J Weinhold; H K Lyerly; K Javaherian; T J Matthews
Journal:  AIDS Res Hum Retroviruses       Date:  1988-06       Impact factor: 2.205

9.  Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies.

Authors:  P L Nara; W G Robey; S W Pyle; W C Hatch; N M Dunlop; J W Bess; J C Kelliher; L O Arthur; P J Fischinger
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

10.  Type-restricted neutralization of molecular clones of human immunodeficiency virus.

Authors:  D J Looney; A G Fisher; S D Putney; J R Rusche; R R Redfield; D S Burke; R C Gallo; F Wong-Staal
Journal:  Science       Date:  1988-07-15       Impact factor: 47.728

View more
  38 in total

1.  Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein.

Authors:  A L Edinger; M Ahuja; T Sung; K C Baxter; B Haggarty; R W Doms; J A Hoxie
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 2.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

3.  Characterization of the cDNA of a broadly reactive neutralizing human anti-gp120 monoclonal antibody.

Authors:  W A Marasco; J Bagley; C Zani; M Posner; L Cavacini; W A Haseltine; J Sodroski
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

4.  Synthetic peptides from a conserved region of gp120 induce broadly reactive anti-HIV responses.

Authors:  W J Morrow; W M Williams; A S Whalley; T Ryskamp; R Newman; C Y Kang; S Chamat; H Köhler; T Kieber-Emmons
Journal:  Immunology       Date:  1992-04       Impact factor: 7.397

5.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.

Authors:  M Thali; J P Moore; C Furman; M Charles; D D Ho; J Robinson; J Sodroski
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

6.  Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.

Authors:  R Wyatt; J Moore; M Accola; E Desjardin; J Robinson; J Sodroski
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

7.  Proposed atomic structure of a truncated human immunodeficiency virus glycoprotein gp120 derived by molecular modeling: target CD4 recognition and docking mechanism.

Authors:  J L Gabriel; W M Mitchell
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

Review 8.  The molecular structure of human antibodies specific for the human immunodeficiency virus.

Authors:  J S Andris; J D Capra
Journal:  J Clin Immunol       Date:  1995-01       Impact factor: 8.317

9.  Human immunodeficiency virus type 1 major neutralizing determinant exposed on hepatitis B surface antigen particles is highly immunogenic in primates.

Authors:  K Schlienger; M Mancini; Y Rivière; D Dormont; P Tiollais; M L Michel
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

10.  Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120.

Authors:  J A McKeating; C Shotton; J Cordell; S Graham; P Balfe; N Sullivan; M Charles; M Page; A Bolmstedt; S Olofsson
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.